Pfizer's Trading Volume Drops 36.9% to $8.10 Billion Ranking 94th Amidst Expansion and FDA Approval

On March 28, 2025, Pfizer's trading volume was $8.10 billion, down 36.9% from the previous day, ranking 94th in the day's stock market. Pfizer (PFE) rose 0.80%.

Pfizer has announced that it will invest $1 billion in expanding its manufacturing facilities in the United States. This investment is part of the company's strategy to increase its production capacity and meet the growing demand for its products. The expansion is expected to create thousands of new jobs and boost the local economy.

Pfizer has also reported that it has received approval from the FDA for a new drug to treat a rare disease. The drug, which has shown promising results in clinical trials, is expected to be a significant addition to Pfizer's portfolio of innovative medicines. The company plans to launch the drug in the coming months and expects it to generate substantial revenue.

In addition, Pfizer has announced that it will acquire a biotechnology company specializing in gene therapy. The acquisition is expected to strengthen Pfizer's position in the gene therapy market and provide it with access to new technologies and expertise. The deal is expected to close in the second half of the year.